Xanadu Bio
Gladwyne, US · Founded 2021 · Delaware corporation
Founders & leadership
TF
Taylor FeehleyinChief Operating Officer
TW
Todd WiderDr. Wider is the Chief Medical Officer of the Issuer.
MS
Mark SaltzmanNamed on SEC filing
BT
Bruce TurnerNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$23M disclosed across 2 rounds · 2022–2025
▶$11MraisedAug 2025 · 4 investors · BiotechnologyRule 506(b)
▶$11MraisedAug 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Taylor FeehleyExecutive Officer
- Mark SaltzmanDirector
- Todd WiderDirector, Executive Officer, Promoter
- Bruce TurnerDirector, Executive Officer, Promoter
- Offering amount
- $11M
- Amount sold
- $11M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$12MraisedDec 2022 · 8 investors · BiotechnologyRule 506(b)
▶$12MraisedDec 2022 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce TurnerExecutive Officer, Director, Promoter
- Mark SaltzmanDirector
- Todd WiderExecutive Officer, Director, Promoter
- Offering amount
- $30M
- Amount sold
- $12M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Xanadu Bio raised?
- Xanadu Bio has disclosed $23M raised across 2 rounds.
- Where is Xanadu Bio headquartered?
- Xanadu Bio is headquartered in Gladwyne, US.